SABS
SAB BiotherapeuticsCNasdaq / Pharmaceuticals, Biotechnology & Life Sciences
Last Price
At close
2026-06-02
Current thesis
The bullish view still rests on SAB-142: management said in the March 9, 2026 release that SAFEGUARD is underway, multiple patients had been dosed, enrollment was on track for end-2026 completion, and the company had operational runway through 2028, which can support continued de-risking if the next update confirms execution [#PR-2026-03-09].
Posture
Mixed
Lead driver
Sentiment
What changed
Sentiment remains the lead driver in the composite, 7D delta +19.1.
What can break
Clinical execution risk remains high because the core thesis depends on timely SAFEGUARD enrollment and later topline data, with limited diversification beyond SAB-142 [#PR-2026-03-09] [#10-K-2026-03-09].
Momentum
42
Value
41
Sentiment
76
Setup hits (3d)
0 · Net Neutral
AI TargetsBase $3.75 · Bull $9.38 · Bear $2.25
Data freshness
Prices
As of 2026-06-02
Fundamentals
As of 2026-05-28 • Vendor: Data Vendor v1
Scores
As of 2026-06-02 • Model: HYBRID_IC_RP
AI Memo
As of 2026-05-09 • Model: RankAlpha Sentiment Codex
Investment thesisAs of 2026-06-02
Investment thesis
As of 2026-06-02
Supporting evidence
What
Grade C · Mixed
Confidence Medium · Net Neutral
Target $9.38
Why
Momentum42 · Δ7d -7.9
Value41 · Δ7d +0.1
Sentiment76 · Δ7d +19.1
So what
Balanced signals (Net Neutral). Wait for confirmation before sizing up.
Lead driver: Sentiment · See AI snapshot
Momentum
42
34% active weight
Current posture
7d trendSoftening
Δ7d
-7.9
Δ21d
+9.8
Value
41
32% active weight
Current posture
7d trendFlat
Δ7d
+0.1
Δ21d
+0.2
Sentiment
76
33% active weight
Current posture
7d trendImproving
Δ7d
+19.1
Δ21d
+18.9
Why this grade
Composite grade C. Momentum 42.2 / Value 41.1 / Sentiment 76.5
Fundamentals (TTM)As of 2026-05-28
Fundamentals (TTM)
As of 2026-05-28
Market Cap
$272.98M
Beta
0.59
Shares Out
47.61M
P/E (TTM) · Derived
-1.6
P/S (TTM)
1552.31
P/FCF (TTM) · Derived
-4.03
Rev YoY
-100.0%
EPS YoY
+106.1%
Gross Margin
-
Op Margin
-37656.5%
Net Debt
-$17.07M
Current Ratio
10.50
As of 2026-06-02 • Updated nightlySource: Internal modelMethodology